Cash, cash equivalents and marketable securities were $1.93B as of September 30. This balance includes the receipt of the first royalty monetization tranche of $250M in June from the company’s partnership with Royalty Pharma, and there remains an additional $1.75B in future committed capital under this arrangement.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RVMD:
- Boeing upgraded, Charter downgraded: Wall Street’s top analyst calls
- Revolution Medicines initiated with an Outperform at RBC Capital
- Revolution Medicines: Promising Oncology Leader with Strategic Advancements and Competitive Edge
- Revolution Medicines Advances RAS(ON) Inhibitor Study in Gastrointestinal Cancers
- Revolution Medicines Advances RAS(ON) Inhibitors in NSCLC Study